CLAIMS

1. Use of a combination consisting of ibuprofen in the form of a pharmaceutically acceptable salt thereof and tramadol, or a pharmaceutical acceptable salt thereof, in the preparation of a drug for the treatment of pain in humans, characterized in that the dosage of ibuprofen in the combination is comprised between 350 mg and 450 mg and the dosage of tramadol or a pharmaceutically acceptable salt thereof in the combination is comprised between 35 mg and 40 mg, expressed as equivalent weight of tramadol hydrochloride.

2. Use of a combination according to claim 1, characterized in that the ibuprofen pharmaceutically acceptable salt is selected form ibuprofen arginate, ibuprofen lysinate and ibuprofen sodium, and preferably is selected from ibuprofen arginate and ibuprofen lysinate.

3. Use of a combination according to claim 2, characterized in that the ibuprofen pharmaceutically acceptable salt is ibuprofen arginate, preferably wherein the molar ratio ibuprofen:arginine is comprised between 1.2:1 and 1:1.2.

4. Use of a combination according to any of claims 1 to 3, characterized in that the dosage of ibuprofen is comprised between 390 mg and 410 mg, and preferably is about 400 mg.

5. Use of a combination according to any of claims 1 to 4, characterized in that the dosage of tramadol, or a pharmaceutically acceptable salt thereof, expressed as equivalent weight of tramadol hydrochloride, is comprised between 36 mg and 39 mg, and preferably is about 37.5 mg.

6. Use of a combination according to any of claims 1 to 5, characterized in that tramadol is in the form of tramadol hydrochloride.

7. Use of a combination according to any of claims 1 to 6, characterized in that the combination is to be administered by the oral route.

8. Use of a combination according to any of claims 1 to 6, characterized in that the combination is to be administered intravenously.

9. Use of a combination according to any of claims 1 to 8, characterized in that is for the treatment of acute pain or chronic pain, preferably of moderate to severe intensity, and more preferably is for the treatment of severe pain.

10. Use of a combination according to any of claims 1 to 9, characterized in that the combination is to be administered in the form of a pharmaceutical composition consisting of the combination of ibuprofen in the form of a pharmaceutically acceptable salt thereof and tramadol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

11. Use of a combination according to any of claims 1 to 10, characterized in that the combination is to be administered in the form of a pharmaceutical composition consisting of the fixed-dose combination of ibuprofen in the form of a pharmaceutically acceptable salt thereof and tramadol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

12. Use of a combination according to claim 10 or 11, characterized in that the pharmaceutical composition is for oral administration and is selected from the group consisting of granules, powders, tablets and capsules.

13. Use of a combination according to claim 10 or 11, characterized in that the pharmaceutical composition is an aqueous solution for intravenous injection.

14. Combination consisting of ibuprofen in the form of a pharmaceutically acceptable salt thereof; and tramadol, or a pharmaceutically acceptable salt thereof; wherein:

- the amount of ibuprofen is comprised between 350 mg and 450 mg; and

- the amount of tramadol or a pharmaceutically acceptable salt thereof, expressed as equivalent amount of tramadol hydrochloride, is comprised between 35 mg and 40 mg.

15. Combination according to claim 14, in the form of a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.

16. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is for oral administration and comprises about 37.5 mg of tramadol hydrochloride, about 400 mg of ibuprofen, arginine in an amount so that the molar ratio ibuprofen:arginine is comprised between 1.2:1 and 1:1.2, and at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is selected from granules, tablets and capsules.

17. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is an aqueous solution for intravenous injection and comprises about 37.5 mg of tramadol hydrochloride, about 400 mg of ibuprofen, arginine in an amount so that the molar ratio ibuprofen:arginine is comprised between 1.2:1 and 1:1.2, and at last one pharmaceutically acceptable excipient.